The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients

Pharmacological Research

Volumn 60, Issue 6, 2009, Pages 519-524

  Richir, M C ^a   Ellger, B ^c,d   Teerlink, T ^a   Siroen, M P C ^a   Visser, M ^a   Spreeuwenberg, M ^a   Girbes, A R J ^a   van der Hoven, B ^b   van den Berghe, G ^c   Wilhelm, A J ^b   de Vries, Th P G M ^b   van Leeuwen, P A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

ADMA; Arginine; Critical illness; MOF; Multiple organ failure; Nitric oxide; Rosiglitazone

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE; ROSIGLITAZONE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HALF LIFE TIME; HUMAN; INTENSIVE CARE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; ARGININE; CRITICAL ILLNESS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; THIAZOLIDINEDIONES;

EID: 70350060153     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.06.007     Document Type: Review

References (37)

1. Andrew P.J., and Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 43 (1999) 521-531
2. Cauwels A. Nitric oxide in shock. Kidney Int 72 (2007) 557-565
3. Forstermann U., Schmidt H.H., Pollock J.S., Sheng H., Mitchell J.A., Warner T.D., et al. Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem Pharmacol 42 (1991) 1849-1857
4. Cooke J.P. Asymmetrical dimethylarginine: the Uber marker?. Circulation 109 (2004) 1813-1818
5. Vallance P., and Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24 (2004) 1023-1030
6. Mittermayer F., Krzyzanowska K., Exner M., Mlekusch W., Amighi J., Sabeti S., et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 26 (2006) 2536-2540
7. Abbasi F., Asagmi T., Cooke J.P., Lamendola C., McLaughlin T., Reaven G.M., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001) 1201-1203
8. Boger R.H., Bode-Boger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
9. Dayal S., and Lentz S.R. ADMA and hyperhomocysteinemia. Vasc Med 10 Suppl. 1 (2005) S27-S33
10. Nijveldt R.J., Teerlink T., van der Hoven B., Siroen M.P.C., Kuik D.J., Rauwerda J.A., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 22 (2003) 23-30
11. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
12. Wang T.D., Chen W.J., Cheng W.C., Lin J.W., Chen M.F., and Lee Y.T. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 98 (2006) 1057-1062
13. Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonca A., Bruining H., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22 (1996) 707-710
14. Teerlink T., Nijveldt R.J., De Jong S., and van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303 (2002) 131-137
15. De Jong S., and Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 353 (2006) 287-289
16. Chapelsky M.C., Thompson-Culkin K., Miller A.K., Sack M., Blum R., and Freed M.I. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 43 (2003) 252-259
17. O'Dwyer M.J., Dempsey F., Crowley V., Kelleher D.P., McManus R., and Ryan T. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care 10 (2006) R139
18. Siroen M.P., Teerlink T., Nijveldt R.J., Prins H.A., Richir M.C., and van Leeuwen P.A. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 26 (2006) 203-228
19. Miyazaki Y., Mahankali A., Matsuda M., Glass L., Mahankali S., Ferrannini E., et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24 (2001) 710-719
20. Pistrosch F., Passauer J., Fischer S., Fuecker K., Hanefeld M., and Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27 (2004) 484-490
21. Vinik A.I., Stansberry K.B., and Barlow P.M. Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus. J Diabetes Complications 17 (2003) 279-285
22. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 (2004) 2728-2735
23. Tao L., Liu H.R., Gao E., Teng Z.P., Lopez B.L., Christopher T.A., et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 108 (2003) 2805-2811
24. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
25. Werner A.L., and Travaglini M.T. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21 (2001) 1082-1099
26. Cox P.J., Ryan D.A., Hollis F.J., Harris A.M., Miller A.K., Vousden M., et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 28 (2000) 772-780
27. Kelly A.S., Thelen A.M., Kaiser D.R., Gonzalez-Campoy J.M., and Bank A.J. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 12 (2007) 311-318
28. Wang S., Jiang J.L., Hu C.P., Zhang X.J., Yang D.L., and Li Y.J. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells. Diabetes Metab Res Rev 23 (2006) 157-164
29. Mittermayer F., Schaller G., Pleiner J., Krzyzanowska K., Kapiotis S., Roden M., et al. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab 92 (2007) 2574-2580
30. Lopez A., Lorente J.A., Steingrub J., Bakker J., McLuckie A., Willatts S., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32 (2004) 21-30
31. Avontuur J.A., Bruining H.A., and Ince C. Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats. Circ Res 76 (1995) 418-425
32. Siroen M.P., van Leeuwen P.A., Nijveldt R.J., Teerlink T., Wouters P.J., and Van den B.G. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality?. Crit Care Med 33 (2005) 504-510
33. Paik W.K., and Kim S. Protein methylase I. Purification and properties of the enzyme. J Biol Chem 243 (1968) 2108-2114
34. Ogawa T., Kimoto M., and Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 264 (1989) 10205-10209
35. Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 (2003) 1455-1459
36. Teerlink T. ADMA metabolism and clearance. Vasc Med 10 Suppl. 1 (2005) S73-S81
37. Baylis C., and Vallance P. Measurement of nitrite and nitrate levels in plasma and urine-what does this measure tell us about the activity of the endogenous nitric oxide system?. Curr Opin Nephrol Hypertens 7 (1998) 59-62